Πλοήγηση ανά Θέμα "Pulmonary Embolism"
Αποτελέσματα 1-15 από 15
-
Analysis of the quality of reporting of randomized controlled trials in anticoagulant versus antiplatelet medication for venous thromboembolism prophylaxis as governed by the CONSORT statement
(2021)Randomized controlled trials (RCTs) are the gold standard research in evaluating healthcare interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement improves the quality of RCTs in an evidence-based ... -
Bilateral Deep Vein Thrombosis and Pulmonary Embolism Due to Right Common Iliac Artery Aneurysm with a Contained Rupture
(2022)Venous thromboembolism (comprising deep venous thrombosis and/or pulmonary embolism) is a common disease, often of multifactorial cause. Focal iliac artery aneurysms are relatively rare, and only a few reports exist in the ... -
A case of balloon pulmonary angioplasty as a palliative therapy in chronic thromboembolic pulmonary hypertension
(2016)[No abstract available] -
Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece
(2017)Background and Objective: Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a major healthcare concern that results in substantial morbidity and mortality with great economic ... -
COVID-19 associated pulmonary embolism with D-dimer values within the referent range: A case report and review of the literature
(2021)OBJECTIVE: COVID-19 is associated with an increased incidence of pulmonary embolism (PE). Elevated D-dimer levels are linked to an increased risk of PE and poor clinical outcome. We reported a case of PE in a COVID-19 ... -
Obesity as a Risk Factor for Venous Thromboembolism Recurrence: A Systematic Review
(2022)Background and Objectives: Venous thromboembolism (VTE) encompasses Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE). The duration of anticoagulant therapy following a VTE event partly relies on the risk of recurrent ... -
-
Real world data regarding the management of cancer-associated thrombosis
(2020)PURPOSE OF REVIEW: Patients with cancer are at high risk for thrombotic events, mainly deep vein thrombosis and pulmonary embolism. Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the ... -
Reduction in Hospitalizations for Respiratory Diseases during the First COVID-19 Wave in Greece
(2021)Introduction: During the first COVID-19 wave, a considerable decline in hospital admissions was observed worldwide. Aim: This retrospective cohort study aimed to assess if there were any changes in the number of patients ... -
Residual pulmonary vascular obstruction as predictor of pulmonary embolism recurrence after a first unprovoked episode
(2018)[No abstract available] -
Right ventricular dilation: The additive effect of mechanical ventilation on pulmonary embolism in Covid-19 patients
(2020)[No abstract available] -
-
Temporal trends in pulmonary embolism prevalence in Greece during 2013–2017
(2021)Background: Pulmonary embolism (PE) epidemiological data about the disease prevalence in the general population are unclear. The present study aims to investigate the prevalence of PE in Greece and the associated temporal ... -
Thrombolysis for massive pulmonary embolism in a patient with hemorrhagic shock
(2016)[No abstract available] -
Transcutaneous carbon dioxide monitoring as a predictive tool for all-cause 6-month mortality after acute pulmonary embolism
(2019)Background: Pulmonary embolism (PE) frequently remains undiagnosed. The partial pressure of carbon dioxide (PaCO2), a surrogate of dead-space ventilation, is useful in the evaluation of the degree of pulmonary artery ...